Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 108

Results For "NAL"

5541 News Found

Lupin receives EIR from USFDA for Pithampur Unit-1 Facility with VAI Classification
Drug Approval | January 09, 2025

Lupin receives EIR from USFDA for Pithampur Unit-1 Facility with VAI Classification

The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection of the facility from September 16 to September 27, 2024


Suven Life Sciences announces first subjects dosed in phase-1 clinical trial of SUVN-I6107
Diagnostic Center | January 09, 2025

Suven Life Sciences announces first subjects dosed in phase-1 clinical trial of SUVN-I6107

The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs


Ayush onsite to enrich experience at Mahakumbh: Prataprao Jadhav
News | January 09, 2025

Ayush onsite to enrich experience at Mahakumbh: Prataprao Jadhav

Services like 24/7 Ayush Multi-OPD clinics, mobile healthcare units, free distribution of Ayush medicines, and yoga camps are there for all visitors


Evonik partners with South Korean ST Pharm to increase its offerings for RNA and nucleic acid delivery
News | January 09, 2025

Evonik partners with South Korean ST Pharm to increase its offerings for RNA and nucleic acid delivery

Increases speed to market for drug developers working on nucleic acid therapeutics


GEON Performance Solutions acquires Foster Corporation
News | January 09, 2025

GEON Performance Solutions acquires Foster Corporation

Acquisition expands high-value medical platform


Elinzanetant meets all primary and secondary endpoints in Phase III study OASIS 4 for treatment of vasomotor symptoms caused by breast cancer treatments
Diagnostic Center | January 09, 2025

Elinzanetant meets all primary and secondary endpoints in Phase III study OASIS 4 for treatment of vasomotor symptoms caused by breast cancer treatments

The study also met all secondary endpoints with a reduction in severity of VMS at weeks 4 and 12, a reduction in frequency of VMS at week 1 as well as improvements in sleep disturbances and menopause related quality of life


ProBioGen expands protein and viral manufacturing to drive continued growth
News | January 09, 2025

ProBioGen expands protein and viral manufacturing to drive continued growth

This strategic move aims to address the increasing global demand for biologics, enhancing ProBioGen's ability to support partners from cell line development t


Lilly to establish new global capability centre in Hyderabad
News | January 09, 2025

Lilly to establish new global capability centre in Hyderabad

Lilly plans to hire approximately more than 1,000 new highly-skilled team members


Biocon Biologics embarks on a three-stage strategic journey
News | January 08, 2025

Biocon Biologics embarks on a three-stage strategic journey

Successfully transformed the organization from a two-country operation focused on development and manufacturing to a fully integrated company with a strong commercial engine bringing us closer to patients in over 120 countries


Nutraceuticals CDMO manufacturer Crius Group to adopt 100% AI-based project implementation
Digitisation | January 07, 2025

Nutraceuticals CDMO manufacturer Crius Group to adopt 100% AI-based project implementation

NutrifyGenie AI, a leading AI-driven platform, was integral in designing scientifically differentiated formulations for a multinational client